[Recent progress in anti-HIM-1 research].
Baba
Masanori
M
Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University 8-35-1, Sakuragaoka, Kagoshima 890-8544, Japan. baba@m.kufm.kagoshima-u.ac.jp
D019380:Anti-HIV Agents / Q000494:pharmacology; D000069446:Atazanavir Sulfate; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D015195:Drug Design; D024882:Drug Resistance, Viral; D000068679:Emtricitabine; D019428:HIV Integrase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009842:Oligopeptides; D011480:Protease Inhibitors / Q000494:pharmacology; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019428:HIV Integrase Inhibitors; D009842:Oligopeptides; D011480:Protease Inhibitors; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D000069446:Atazanavir Sulfate; D000068679:Emtricitabine